We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Reasons to Add Tandem Diabetes Stock to Your Portfolio Right Now
Read MoreHide Full Article
Key Takeaways
TNDM's pay-as-you-go pharmacy model gained traction, with pharmacy sales at 6% of U.S. sales.
Tandem Diabetes maintained 2026 guidance, including revenues of about $1.065-$1.085B.
TNDM ended Q1 2026 with $570.3M in cash and investments and no short-term debt.
Tandem Diabetes Care, Inc.’s (TNDM - Free Report) appears well positioned for growth, supported by its successful strategic business model transition. The company's expanding international presence is expected to serve as a key growth driver in the coming quarters, while its strong solvency profile provides additional financial stability. However, macroeconomic headwinds and their potential impact on demand and operating performance remain concerns.
In the past year, this Zacks Rank #2 (Buy) company’s shares have plunged 10.7% compared with the industry’s 6.6% decline. The S&P 500 composite has risen 31% in the said time frame.
The renowned medical device company has a market capitalization of $1.31 billion. Tandem Diabetes projects a growth rate of 73.3% for 2026 earnings compared with 14% for the industry.
Let’s delve deeper.
TNDM’s Key Tailwinds
Business Model Transition Adds Levers: Tandem launched a pay-as-you-go reimbursement model in the U.S. pharmacy channel, building on expanded pharmacy benefit coverage and prior progress moving t:slim supplies into pharmacy. In first-quarter 2026, pharmacy sales represented 6% of U.S. sales, showing early traction but still leaving a long runway for mix shift.
Management reaffirmed 2026 guidance for revenues of about $1.065 billion to $1.085 billion, gross margin of about 56% to 57% and adjusted EBITDA margin of about 5% to 6%. Zacks’ full-year 2026 revenue estimate is pegged at about $1.07 billion.
This framework suggests that the near-term impact of the transition is already incorporated into the company's outlook, while the longer-term upside stems from lower upfront barriers to pump adoption and higher recurring supply revenues as customer utilization increases.
International Expansion Supports Mix: International markets remain less penetrated than the United States and provide room for sustained adoption if local commercialization improves. In first-quarter 2026, international sales grew and the company noted currency favorability compared with the prior year. Tandem is also transitioning portions of its business to direct operations in select countries, which can increase visibility into demand and strengthen the end-customer experience over time.
Management expects some timing-related effects from the initial go-direct rollout but has maintained its full-year guidance framework. With Mobi poised for a broader launch beyond the United States, the company has multiple avenues to expand pump starts and grow recurring supply revenues in international markets.
Image Source: Zacks Investment Research
Liquidity Supports Execution: Tandem ended first-quarter 2026 with $570.3 million of cash, cash equivalents and short-term investments and further reinforced its balance sheet by closing a 0.00% convertible debt offering due 2032. The company had no short-term debt at the quarter’s end.
Operating cash flow was $11 million in first-quarter 2026, supported by higher gross profit and lower year-ago comparable that included acquired IPR&D expense. This liquidity can fund inventory, product development and the planned international buildout without forcing near-term equity issuance.
Concern for TNDM
Macro and Reimbursement Sensitivity: Tandem remains unprofitable, and management is implementing a pay-as-you-go model that reduces upfront costs for customers but may affect the timing of revenue recognition.
If inflation, labor expenses or logistics costs rise more rapidly than anticipated, the company's targeted gross margin expansion could come under pressure. Any slowdown in new customer starts or delays in reimbursement decisions may also extend the time needed for achieving its 2026 profitability and cash flow goals.
Estimate Trend
The Zacks Consensus Estimate for 2026 loss per share has narrowed 8 cents to 91 cents in the past 30 days.
The Zacks Consensus Estimate for 2026 revenues is pegged at $1.08 billion, which suggests an increase of 6% from the year-ago reported number.
Globus Medical has an earnings yield of 6.1% compared to the industry’s negative 1.1% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 26.3%. GMED shares have rallied 28.1% against the industry’s 12.5% decline over the past year.
Alcon, carrying a Zacks Rank #2, has an earnings yield of 5.2% against the industry’s negative 2.2% yield. Shares of the company have risen 6.6% compared with the industry’s 0.5% growth. ALC’s earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 3.7%.
Phibro Animal Health, carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.1%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 16.3%. PAHC’s shares have rallied 41.8% against the industry’s 32.8% decline over the past year.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Reasons to Add Tandem Diabetes Stock to Your Portfolio Right Now
Key Takeaways
Tandem Diabetes Care, Inc.’s (TNDM - Free Report) appears well positioned for growth, supported by its successful strategic business model transition. The company's expanding international presence is expected to serve as a key growth driver in the coming quarters, while its strong solvency profile provides additional financial stability. However, macroeconomic headwinds and their potential impact on demand and operating performance remain concerns.
In the past year, this Zacks Rank #2 (Buy) company’s shares have plunged 10.7% compared with the industry’s 6.6% decline. The S&P 500 composite has risen 31% in the said time frame.
The renowned medical device company has a market capitalization of $1.31 billion. Tandem Diabetes projects a growth rate of 73.3% for 2026 earnings compared with 14% for the industry.
Let’s delve deeper.
TNDM’s Key Tailwinds
Business Model Transition Adds Levers: Tandem launched a pay-as-you-go reimbursement model in the U.S. pharmacy channel, building on expanded pharmacy benefit coverage and prior progress moving t:slim supplies into pharmacy. In first-quarter 2026, pharmacy sales represented 6% of U.S. sales, showing early traction but still leaving a long runway for mix shift.
Management reaffirmed 2026 guidance for revenues of about $1.065 billion to $1.085 billion, gross margin of about 56% to 57% and adjusted EBITDA margin of about 5% to 6%. Zacks’ full-year 2026 revenue estimate is pegged at about $1.07 billion.
This framework suggests that the near-term impact of the transition is already incorporated into the company's outlook, while the longer-term upside stems from lower upfront barriers to pump adoption and higher recurring supply revenues as customer utilization increases.
International Expansion Supports Mix: International markets remain less penetrated than the United States and provide room for sustained adoption if local commercialization improves. In first-quarter 2026, international sales grew and the company noted currency favorability compared with the prior year. Tandem is also transitioning portions of its business to direct operations in select countries, which can increase visibility into demand and strengthen the end-customer experience over time.
Management expects some timing-related effects from the initial go-direct rollout but has maintained its full-year guidance framework. With Mobi poised for a broader launch beyond the United States, the company has multiple avenues to expand pump starts and grow recurring supply revenues in international markets.
Image Source: Zacks Investment Research
Liquidity Supports Execution: Tandem ended first-quarter 2026 with $570.3 million of cash, cash equivalents and short-term investments and further reinforced its balance sheet by closing a 0.00% convertible debt offering due 2032. The company had no short-term debt at the quarter’s end.
Operating cash flow was $11 million in first-quarter 2026, supported by higher gross profit and lower year-ago comparable that included acquired IPR&D expense. This liquidity can fund inventory, product development and the planned international buildout without forcing near-term equity issuance.
Concern for TNDM
Macro and Reimbursement Sensitivity: Tandem remains unprofitable, and management is implementing a pay-as-you-go model that reduces upfront costs for customers but may affect the timing of revenue recognition.
If inflation, labor expenses or logistics costs rise more rapidly than anticipated, the company's targeted gross margin expansion could come under pressure. Any slowdown in new customer starts or delays in reimbursement decisions may also extend the time needed for achieving its 2026 profitability and cash flow goals.
Estimate Trend
The Zacks Consensus Estimate for 2026 loss per share has narrowed 8 cents to 91 cents in the past 30 days.
The Zacks Consensus Estimate for 2026 revenues is pegged at $1.08 billion, which suggests an increase of 6% from the year-ago reported number.
Other Key Picks
Some other top-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Alcon (ALC - Free Report) and Phibro Animal Health (PAHC - Free Report) .
Globus Medical has an earnings yield of 6.1% compared to the industry’s negative 1.1% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 26.3%. GMED shares have rallied 28.1% against the industry’s 12.5% decline over the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Alcon, carrying a Zacks Rank #2, has an earnings yield of 5.2% against the industry’s negative 2.2% yield. Shares of the company have risen 6.6% compared with the industry’s 0.5% growth. ALC’s earnings surpassed estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 3.7%.
Phibro Animal Health, carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.1%. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 16.3%. PAHC’s shares have rallied 41.8% against the industry’s 32.8% decline over the past year.